Categories: News

NYSE Content Advisory: Pre-Market Update + NYSE Hosts 102nd Annual Tree Lighting

NEW YORK, Dec. 4, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Kristen Scholer delivers the pre-market update on December 4th

- Advertisement -
  • The NYSE hosts its 102nd annual tree lighting beginning at 3:30 PM ET today, featuring performances by Deborah Cox and Kelsie Watts, with Hank Azaria and NYSE President Lynn Martin lighting the 75-foot spruce around 6 PM ET.
  • Stocks are little changed this morning as the S&P 500 consolidates recent gains after rising in seven of the past eight sessions.
  • Rates are expected to be cut at the next Fed Meeting as markets see close to a 90% chance the Federal Reserve will lower interest rates next week.

Opening Bell
New America Acquisition Corp rings the Opening Bell

- Advertisement -

Closing Bell
The NYSE celebrates the 102nd annual tree lighting

- Advertisement -

Click here to download the NYSE TV App

- Advertisement -

Video – https://mma.prnewswire.com/media/2838721/NYSE_Market_Update_Dec_4.mp4
Logo – https://mma.prnewswire.com/media/2581322/5656394/New_York_Stock_Exchange_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update–nyse-hosts-102nd-annual-tree-lighting-302633139.html

- Advertisement -

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

3 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

3 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

3 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

3 hours ago